Dichlorobenzene

NVIDIA, BPIPO, DCB, and TITA hosted a seminar on AI-powered drug development, emphasizing AI's role in biotech and techbio integration, precision medicine, and accelerating drug discovery with generative AI, showcasing Taiwan's potential in AI-driven biopharma innovation.

Google DeepMind's AlphaFold 3, an AI model for molecular modeling, promises to revolutionize drug discovery and molecular biology by predicting complex interactions between proteins, DNA, RNA, and small molecules. Released as open-source with some commercial restrictions, it offers unprecedented speed and precision in simulating molecular interactions, potentially accelerating discoveries across various fields.

Taiwan's delegation, led by DCB and BPIPO, showcased advanced biotech at BioJapan 2024, fostering international collaboration. The delegation visited Shonan iPark and engaged with JPMA, promoting bilateral partnerships. The 'Taiwan Biotech Industry Pavilion' highlighted diverse technologies, including iPSC-based therapies and CAR-T treatments. BPIPO also hosted a seminar on startup fundraising and hospital collaboration, while DCB signed an MoU with Rakuten Medical for cancer therapy innovation.

Taiwan's DCB and BPIPO, led by President Shiing-Jer Twu and Director Michael Huang, participated in Bio Asia Pacific 2024 in Bangkok, promoting biotech collaboration. The Taiwan-Thailand Biotechnology Industry Technical Engagement Forum highlighted innovations in precision medicine, genetic testing, and personalized healthcare. Networking events and facility visits reinforced Taiwan's commitment to strengthening ties with Thailand in biotechnology and pharmaceutical sectors.